Carla J. Greenbaum, MD
Dr. Greenbaum received her undergraduate and medical degrees at Brown University then pursued her endocrinology fellowship at University of Washington, where she continues as clinical faculty. She joined the Benaroya Research Institute (BRI) in 2000, where she is a Member and serves as Director of the Diabetes Research Program and the BRI Clinical Research Center. Dr. Greenbaum serves on the Board of Directors for BRI and is a member of the BRI Institutional Review Board, which provides oversight for clinical studies.
Area of Research
Dr. Greenbaum is a clinical investigator who focuses on the natural history of type 1 diabetes, specifically with prediction of disease and interventions to alter immune-mediated beta cell function. She has conducted studies evaluating beta cell function and other physiologic and immune changes that occur during the progression of the natural history of type 1 diabetes.
In addition to clinical trials, she works to facilitate translational research initiatives locally and nationally. Her considerable expertise includes clinical trial design and implementation, and evaluation of biomarkers for disease course and response to therapy. She currently serves as Chair of Type 1 Diabetes TrialNet, an NIH sponsored international consortium to conduct multiple clinical trials in type 1 diabetes. Dr. Greenbaum is the PI for the TrialNet Northwest Clinical Center and in this role, she is responsible for protocol development and clinical issues. In addition, she leads the TrialNet Clinical Network Hub, a newer NIDDK initiative which works collaboratively with the TrialNet Coordinating Center and other clinical centers nationwide to identify and implement sustainable, scalable processes and improvements within the TrialNet consortium. She is also involved with clinical trials with the NIH-sponsored Immune Tolerance Network and the Diabetes Vaccine Development Center in Australia, as well as Phase I/II pharmaceutical trials. Dr. Greenbaum is a member of the University of Washington’s CTSA leadership group. She serves on various national and international scientific review committees focusing on clinical and translational research.
Yang J, James EA, Sanda S, Greenbaum C, Kwok WW. CD4+ T cells recognize diverse epitopes within GAD65: implications for repertoire development and diabetes monitoring. Immunology, Mar;138(3):269-79, 2013 [PMID: 23228173, PMCID: 3573280].
Long SA, Rieck M, Sanda S, Bollyky JB, Samuels PL, Goland R, Ahmann A, Rabinovitch A, Aggarwal S, Phippard D, Turka LA, Ehlers MR, Bianchine PJ, Boyle KD, Adah SA, Bluestone JA, Buckner JH, Greenbaum CJ; for Diabetes TrialNet and the Immune Tolerance Network: Rapamycin/IL-2 Combination Therapy in Patients with Type 1 Diabetes Augments Tregs yet Transiently Impairs Cell Function. Diabetes, Sep;61(9):2340-8, 2012 [PMID: 22721971, PMCID: 3425404].
Greenbaum CJ, Beam CA, Boulware D, Gitelman SE, Gottlieb PA, Herold KC, Lachin JM, McGee P, Palmer JP, Pescovitz MD, Krause-Steinrauf H, Skyler JS, Sosenko JM; on behalf of the Type 1 Diabetes TrialNet Study Group. Fall in C-peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite TrialNet Data. Diabetes, Aug;61(8):2066-73, 2012 [PMID: 22688329, PMCID: 3402330].
Sosenko JM, Skyler JS, Mahon J, Krischer JP, Beam CA, Boulware DC, Greenbaum CJ, Rafkin LE, Cowie C, Cuthbertson D, Palmer JP; the Type 1 Diabetes TrialNet and Diabetes Prevention Trial-Type 1 Study Groups. The Application of the Diabetes Prevention Trial-Type 1 Risk Score for Identifying a Preclinical State of Type 1 Diabetes. Diabetes Care, Jul;35(7):1552-5, 2012 (Epub ahead of print) [PMID: 22547092, PMCID: 3379597].
Yu L, Boulware DC, Beam CA, Hutton JC, Wenzlau JM, Greenbaum CJ, Bingley PJ, Krischer JP, Sosenko JM, Skyler JS, Eisenbarth GS, Mahon JL; for the Type 1 Diabetes TrialNet Study Group. Zinc Transporter-8 Autoantibodies Improve Prediction of Type 1 Diabetes in Relatives Positive for the Standard Biochemical Autoantibodies. Diabetes Care, June;35(6):1213-8, 2012 [PMID: 22446173, PMCID: 3357246].
Pescovitz MD, Torgerson TR, Ochs HD, Ocheltree E, McGee P, Krause-Steinrauf H, Lachin JM, Canniff J, Greenbaum C, Herold KC, Skyler JS, Weinberg A: Type 1 Diabetes TrialNet Study Group. Effect of rituximab on human in vivo antibody immune responses. J Allergy Clin Immunol, Dec;128(6):1295-1302, 2011 [PMID: 21908031, PMCID: 3659395].
Xu P, Cuthbertson DD, Greenbaum CJ, Palmer JP, Krischer JP: The Role of Insulin Resistance in Predicting the Progression to Type 1 Diabetes. Diabetes Care, Sep;30(9):2314-20, 2007 [PMID: 17536068]